Restructuring Charges (Notes)	3 Months Ended
Restructuring Charges (Notes)	Mar. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Charges In January 2014, Lexicon’s board of directors committed to narrow its strategic initiatives and focus resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, in preparation for the transition to commercialization. The decision will result in a workforce reduction of approximately 125 employees, primarily in research, discovery and support positions, representing approximately 50% of the Company’s total workforce. The Company expects to complete the majority of the workforce reduction by the end of the second quarter of 2014. The Company currently expects that the total charges associated with the restructuring that will result in cash expenditures will be approximately $5.8 million to $6.3 million (which includes charges for severance of approximately $5.3 million and other restructuring costs of approximately $0.5 million to $1.0 million), of which $4.0 million was incurred through March 31, 2014. Of this charge, $3.6 million was recorded in research and development expense and $0.4 million was recorded in general and administrative expense in the accompany consolidated statement of comprehensive loss for the three months ended March 31, 2014. In addition, the Company recorded stock-based compensation expense on the acceleration of vesting relating to the restructuring of $0.1 million in the three months ended March 31, 2014. Future payments of restructuring charges, which have been recorded in accrued liabilities in the accompanying consolidated balance sheet, was $1.1 million as of March 31, 2014.

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details